SoftBank's Masayoshi Son tearfully laments selling $160 billion Nvidia stake for $4 billion, shifting focus to new $100 billion fund aimed at realizing artificial superintelligence.
SoftBank Group soars with a remarkable $2.87 billion profit in the first quarter, fueled by substantial gains from its Vision Fund investments, while its Stargate data center project faces a slight delay and it raises $7.8 billion from offloading T-Mobile shares.
In a groundbreaking move, Samsung secures a deal to manufacture advanced three-layer stacked camera sensors for Apple's upcoming iPhone 18 at its Texas facility, challenging Sony's long-standing dominance as the sole supplier and allowing Apple to circumvent tariffs on foreign-made chips.
SoftBank exits its 23-year partnership with Alibaba, reaping a staggering $8.5 billion windfall, 425 times its initial $20 million investment, as co-founders Jack Ma and Joe Tsai become Alibaba's largest shareholders.
SoftBank CEO Masayoshi Son tearfully laments selling his $3.6 billion Nvidia stake in 2019 for $160 billion loss, launches $100 billion AI fund named Izanagi.
Elon Musk unveils plans to integrate advertisements into X's AI assistant Grok, enabling advertisers to pay for product placements in its responses as part of X's monetization strategy, leveraging xAI technology for improved ad targeting on the social network.
Pioneering users unveil groundbreaking applications of ChatGPT 5, showcasing its versatility in revolutionizing work, business, and daily life through innovative use cases that push the boundaries of this cutting-edge technology.
AI model Perch empowers conservationists to safeguard endangered species through improved bioacoustic analysis, recognizing specific sounds, adapting to new environments like coral reefs, and allowing open-source monitoring of biodiversity.
In a groundbreaking development, scientists unveil an AI model capable of accurately pinpointing the location of any protein within human cells, combining protein language models and computer vision to capture intricate details, potentially revolutionizing disease diagnosis, drug target identification, and our understanding of biological processes.
GPT-5 debuts on Augment, offering users a choice between speed and thoroughness alongside Claude Sonnet 4, as Augment monitors usage data to optimize future model tuning.